GCM
KYNB

Graham Capital Management’s Kyntra Bio KYNB Stock Holding History

Graham Capital Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-3,599
Closed -$80.3K – 1172
2024
Q2 		$80.3K Buy
+3,599
New +$111K ﹤0.01% 960
2023
Q3 		– Sell
-467
Closed -$31.5K – 1105
2023
Q2 		$31.5K Buy
+467
New +$193K ﹤0.01% 925

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GC
GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

Graham Capital Management's KYNB Position: Q3 2024 in Review

Graham Capital Management sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 3,599 shares — an estimated $80.3K sold.

Graham Capital Management first reported a position in KYNB in Q2 2023 and held it in 2 quarters. The position peaked at $80.3K in Q2 2024. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

  • Graham Capital Management reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
  • Graham Capital Management sold 3,599 Kyntra Bio shares in Q3 2024, an estimated $80.3K.
  • Graham Capital Management first reported a position in Kyntra Bio in Q2 2023 and held it in 2 quarters.
  • Graham Capital Management's Kyntra Bio position peaked at $80.3K in Q2 2024.
  • 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on Graham Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.